May 15, 2024 · Tizona Therapeutics is developing cancer treatments that have the potential to be first- and best-in-class treatments, and core components of immunotherapy combination …

Our oncology pipeline is focused on restoring and bolstering immune responses. Tizona is enrolling patients in two randomized arms within the ongoing Phase 1b clinical trial …

Tizona Therapeutics is applying novel scientific insights to change the course of cancer progression and relapse.

Christine O’Brien is the Chief Executive Officer for Tizona and a member of the Board of Directors. O’Brien joined Tizona in 2015 and served most recently as the Chief Operating Officer.

Jul 21, 2020 · Tizona equity holders will be eligible to receive up to $1.25 billion in an option exercise fee and potential future milestone payments. Gilead will also provide funding to …

Here at Tizona Therapeutics, we value Patients First! With this goal in mind, Tizona develops next-generation immunotherapies. Join us today.

May 23, 2024 · Tizona translates scientific breakthroughs into therapeutics that stimulate the immune system and counter immune suppression. Tizona’s pipeline includes TTX-080 , which …

Table 6. Treatment-Related Adverse Events of TTX-080 + Cetuximab in mHNSCC Patients TRAE reported in ≥5% of patients Grade 1 Grade 2 Grade 3 Grade 4 Total (N=23)

Tizona Therapeutics, Inc. is located at 4000 Shoreline Court, Suite 200 South San Francisco, CA 94080

Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal …